Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference ...

There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...

Vertex Pharmaceuticals (NASDAQ: VRTX ... I'm talking about suzetrigine for moderate-to-severe acute pain. Image source: Getty ...

Data showed the US economy grew faster than previously estimated in the third quarter, while weekly jobless claims fell more ...

The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's sell-off despite upbeat data on economic growth.

Korea prepares for advances in obesity drugs, space exploration, and upcoming policies Korea sets sights on breakthroughs in ...

Biopharma companies like Vertex Pharmaceuticals have pathbreaking ... valuations. SOPA Images/LightRocket via Getty Images 10) Digital Health Will Continues to Spin Lots of digital health ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday.Pick the best stocks and ...